Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.36 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3927012 | 0.89 | PDE4B (0.38) | GRM5CYP11B1CYP11B2CYP19A1CYP2C9 | |
| SCHEMBL3931122 | 0.86 | KMT2A (0.43) | CYP19A1SMPD1MEN1ALDH1A1GAA | |
| SCHEMBL3925115 | 0.85 | KDM4E (0.40) | CYP11B1CYP11B2CYP19A1CYP2C9SMPD1 | |
| SCHEMBL3925114 | 0.85 | KDM4E (0.40) | CYP11B1CYP11B2CYP19A1CYP2C9SMPD1 | |
| SCHEMBL3927709 | 0.84 | MAOB (0.40) | GRM5SMPD1MEN1ALDH1A1GAA | |
| SCHEMBL3934029 | 0.81 | DYRK1B (0.42) | GRM5DYRK1AMEN1ALDH1A1MAPT | |
| SCHEMBL3925118 | 0.81 | BRD4 (0.32) | GRM5MEN1ALDH1A1GAAMAPT | |
| SCHEMBL3933515 | 0.78 | LRRK2 (0.43) | CYP11B1CYP11B2SMPD1MEN1ALDH1A1 | |
| SCHEMBL3929916 | 0.78 | DYRK1B (0.40) | DYRK1AMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL3926276 | 0.78 | VNN1 (0.37) | SMPD1MEN1ALDH1A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090093479-A1 | ANTI-CANCER AGENTS AND USES THEREOF | LOCUS PHARMACEUTICALS, INC. (US) | 2009-04-09 | — | — | US | disclosed |
| US-7504401-B2 | Anti-cancer agents and uses thereof | LOCUS PHARMACEUTICALS, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-20080280891-A1 | Anti-cancer agents and uses thereof | LOCUS PHARMACEUTICALS, INC. (US) | 2008-11-13 | — | — | US | disclosed |
| WO-2008008059-A1 | ANTI-CANCER AGENTS ANS USES THEREOF | LOCUS PHARMACEUTICALS, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| US-20060270686-A1 | Anti-cancer agents and uses thereof | LOCUS PHARMACEUTICALS, INC. | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093479-A1 | ANTI-CANCER AGENTS AND USES THEREOF | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MCL1, CBR3 | GRM5 1826/4885CYP11B1 1504/4885CYP11B2 2214/4885 |
| US-20060270686-A1 | Anti-cancer agents and uses thereof | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MCL1, CBR3 | GRM5 1810/4885CYP11B1 1407/4885CYP11B2 2099/4885 |
| US-20080280891-A1 | Anti-cancer agents and uses thereof | NR2E3, RB1, CBR3 | GRM5 2240/4885CYP11B1 615/4885CYP11B2 1137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.